Nanored develops nanotechnology for medical applications, with a focus on a new platform to prevent and treat SARS-CoV-2. The firm's primary platform prevents SARS-CoV-2 from attacking and entering vulnerable cells in the lungs while delivering genomic medicines to at-risk lung cells to prevent the virus from replicating. This platform has applications for fighting lung cancer cells and can be adapted to prevent and treat future respiratory viral pandemics. The platform utilizes photoactivateable liposomes that are loaded with a therapeutic payload and infused intravenously. The liposomal formulation utilizes an IR-sensitizing agent to allow physicians to illuminate the tumor region, which destabilizes the liposomal after it reaches the appropriate wavelength. This solution offers a number of advantages over existing platforms.
